ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR/Anti-MUC1 Bispecific Antibody-drug Conjugate NEOK002

Also written as “NEOK002” and “NEOK002 RDE”.

Its studies are led by NEOK Bio.

Furthest: phase 1, since May 21, 20261 company-led study, 1 open or runningNext primary completion: Feb 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NEOK Bio11 open or runningphase 1since May 21, 2026May 21, 2026Feb 2029phase 1 · NCT07612189

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2026First study: phase 1 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsFirst studyNCT07612189 · 155 planned · United States

Ahead

  1. Feb 2029Primary completion: phase 1 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT07612189

TargetBeta

EGFR →MUC1 →read by rule
“An antibody drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) human epidermal growth factor receptor (EGFR; HER1; ErbB1) and mucin-1 (MUC1) ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07612189Locally Advanced (Unresectable) or Metastatic Solid Tumors · United States1RecruitingFeb 2029155

How it is read

Names in the registry

  • “NEOK002”, 1 entry
  • “NEOK002 RDE”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.